泰山学术论坛—肿瘤免疫及治疗专题举办方案

一、组织机构

主办单位：山东省教育厅

承办单位：鲁东大学

二、论坛时间

2015年9月18-20日

三、举办地点

鲁东大学接待服务中心

四、主题内容

为促进肿瘤医学领域同行间的交流与合作，推动我国肿瘤免疫治疗的快速发展和技术创新，本论坛“肿瘤免疫及治疗”专题国际研讨会，特邀请本领域国际、国内知名专家学者就肿瘤免疫和癌症免疫治疗的最新研究热点、研究进展和临床应用、发展趋势等做专题报告。同时，邀请会议参加者通过会议发言、墙报展示、论文投稿等形式进行讨论和交流。宗 旨是为从事肿瘤免疫和癌症免疫治疗研究和临床应用领域的国内外同行学者搭建一个广泛、深入交流的平台，介绍、讨论和展望在肿瘤发生的分子机制、先天免疫和 获得性免疫在癌症发生中的调控作用、癌症免疫治疗新技术新方法等领域的最新研究成果和临床应用前景，探讨本领域发展所面临的关键性挑战问题和研究方向，为 进行国内、国际间的科研合作和临床应用创造条件。

主要议题：

（一）肿瘤发生的分子机制

（二）先天免疫在癌症发生中的作用

（三）肿瘤微环境

（四）肿瘤抗原与癌症疫苗

（五）免疫抑制与肿瘤逃逸

（六）细胞因子与癌症治疗

（七）癌症的蛋白与抗体治疗

（八）癌症的被动免疫细胞治疗

（九）癌症的联合治疗

（十）癌症治疗的新技术

五、论坛议程

六、联系方式

联系人：解卫海，电话86+0535-6685003，手机15589537077，电子信箱：xieweihai1973@126.com。

联系人：周菊华，电话：86+0535-6642910，手机：18300501903, 电子信箱：1921358071@qq.com。

通信地址：山东省烟台市红旗中路186号

七、专家介绍

1．Olivera (Olja) J. Finn, PhD，Chair and Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA.

Dr. Finn’s research interests and expertise are in the areas of tumor immunology, transplant immunology and T-cell biology. In particular, her group has identified a novel immune response to a tumor-associated antigen, MUC1, expressed on breast, pancreatic, colon, ovarian and other carcinomas of epithelial cell origin. This work has led to the development of a potential cancer vaccine based on the protein cyclin B1 that is currently being tested in clinical trials.

Dr. Finn is a recipient of the American Cancer Society Faculty Award, UPCI’s Scientific Leadership Award, University of Pittsburgh Chancellor’s Distinguished Research Award, University of Pittsburgh Mentor of the Year Award and Department of Molecular Genetics and Biochemistry Faculty Award.

Dr. Finn is very active and influential in professional societies important to program members including the American Association of Immunologists, American Association for Cancer Research and Women in Cancer Research. She serves as liaison between the societies and the program members. She also is an active participant in National Cancer Institute (NCI) activities, which allow her to be familiar with many new NCI initiatives that she can quickly transmit to the members.

Dr. Finn is a member of scientific advisory boards of several cancer centers in the United States and Canada, and she is a member of editorial boards of several journals in the field of tumor immunology.

2．Cassian Yee, M.D., Professor, Department of Melanoma Medical Oncology; Professor, Department of Immunology; Director, Solid Tumor Cell Therapy, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, 7455 Fannin Street, Houston, TX 77054, USA.

Dr. Cassian Yee is a professor in the Department of Melanoma Medical Oncology and Department of Immunology at UT MD Anderson Cancer Center. He also serves as the Director of the Solid Tumor Cell Therapy Program there. After receiving his medical degree from the University of Manitoba in Canada, Dr. Yee trained as a research fellow at the Ontario Cancer Institute in Toronto and continued his medical residency at Stanford University. He completed a fellowship in medical oncology and postdoctoral research studies at the University of Washington and the Fred Hutchinson Cancer Research Center.

Dr. Yee is a recipient of the Cancer Research Institute Investigator Award and the Damon Runyon Walter Winchell Clinical Investigator Award. He is also a Burroughs Wellcome Scientist in Translational Research and elected member of the American Society for Clinical Investigation, and co-leader of the Stand Up to Cancer Immunology Dream Team.

Dr. Yee’s research was among the first to show that adoptive T-cell therapy holds great promise for treating melanoma, a potentially fatal form of skin cancer. His team described the first successful use of a patient’s own T-cells as the sole therapy to put advanced melanoma into long-term remission. Additionally, he demonstrated for the first time that human T cells can become long-lasting memory cells after infusion and, when combined with a checkpoint inhibitor, halt tumor growth in patients with metastatic melanoma. Using this combinational approach, Dr. Yee’s team seeks to develop adoptive T cell therapy as a clinically feasible treatment modality for patients with solid tumor malignancies in general.

3．Kyung-Mi Lee, Professor, Department of Biochemistry, Korea University Medical School, Anam-Dong 5-Ga, Sungbukku, Seoul, 136-705, Korea

4．Ben C. Valdez, Ph.D., Associate Professor, Department of Stem Cell Transplantation – Research, The University of Texas MD Anderson Cancer Center, 7455 Fannin Street, Houston, TX 77054, USA.

Dr. Ben Valdez’s research interests focus on the identification of genes involved in cellular resistance of leukemia and lymphoma cells to drugs used in preconditioning therapy prior to stem cell transplantation. Using genetics and biochemical approaches to dissect the mechanisms of drug resistance, he hope to identify gene products and signal transduction pathways that can be pharmacological targets to sensitize cancer cells to chemotherapy. Moreover, identification of genes that confer resistance to specific anti-cancer drug will be relevant to administration of appropriate alternative treatment modality to leukemia and lymphoma patients.

Dr. Valdez’s laboratory uses drug combinatorial approach to make cancer cells sensitive to chemotherapy. Specifically, they combine nucleoside analogs and DNA alkylating agents and determine their mechanism of synergistic cytotoxicity. They recently proposed a model suggesting that nucleoside analogs induce chromatin remodeling and make genomic DNA more accessible to DNA alkylators resulting in massive DNA damage and cell killing. Results from these studies are used as preclinical basis for proposing clinical trials.

Dr. Ben Valdez is also interested in the roles of the nucleolus in carcinogenesis and drug resistance. Recent findings suggest the function of the nucleolus in the regulation of p53 activity. He has done functional studies of some nucleolar proteins including their putative roles in human diseases, and he plans to relate these findings with the proliferation of leukemia cells.

5．Kui Shin Voo, Ph.D., Assistant Professor, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 7455 Fannin Street, Houston, TX 77054, USA.

Dr. Voo obtained his PhD degree from North Carolina State University, USA. He is currently working as an Assistant Professor in the Department of Genomic Medicine, and Senior Scientist at Research for Biologics and Immunotherapy Translation (ORBIT) at MD Anderson Cancer Center, USA. Dr.Voo has over 15 years of experience in tumor immunology and immunotherapy. His research efforts are primarily focused on development of therapeutic antibodies for malignancies. He has successfully developed antibodies against OX40 that is in phase I clinical trial.

6．管敏鑫，博士，教授，博士生导师，浙江大学遗传学研究所所长，国家“千人计划” 特聘专家，"973"计划项目首席科学家。长期从事线粒体遗传学和母系遗传性疾病的基础研究和临床转化。曾先后获得美国国立卫生研究院多项研究基金，联合线粒体病基金会科研成果奖和美国耳聋基金会优秀学者奖等。1983年毕业于杭州大学生物系。1989年赴澳大利亚国立大学留学，获博士学位。1993-1996年在美国加州理工学院做博士后研究，1996年至1999年受聘为美国加州理工学院生物系高级研究员。1999年至2011年起在全美国儿童医院排名第三的辛辛那提大学儿童医院医学中心任人类遗传学终身教授、博士及博士后导师，线粒体遗传学研究室主任。自2011年全职回国后，主持国家重点基础研究发展计划（973计划），“十二五”国家科技支撑计划，国家自然科学基金重点项目等多项课题。已在母系遗传性聋病、癌症、高血压和Leber遗传性视神经病变致病机理和tRNA转录后修饰的机制等领域发表论文共174篇，其中在Cell， Am J Hum Genet，Hum Mol Genet，Circulation Research，Ophthalmology等本领域国际权威学术期刊上发表SCI论文100多篇。曾获国家科技进步二等奖、谈家桢生物科学创新奖等多项奖励。主编出版《医学遗传学》等教材。

7．陈策实，博士，研究员，博士生导师，中国科学院昆明动物研究所，百人计划，杰青（2013）。1994年毕业于南开大学微生物系，获学士学位。1999 年获中国科学院上海生物工程研究中心和药物研究所药理学博士学位。1999-2005年先后在美国University of Virginia病理系和Emory University Winship癌症研究所从事博士后研究。2006起在Albany Medical College细胞生物学和癌症研究中心任独立的助理教授，2009年晋升为副教授。长期从事肿瘤细胞生物学研究，2010年全职回到国内工作。

从 事肿瘤分子细胞生物学研究长达15年，首次在乳腺癌和前列腺癌发现了多个重要癌症相关基因如KLF5。并对其遗传突变、作用与调节机制进行了深入系统研 究，鉴定出一批新的候选靶标用于肿瘤临床诊治和预后以及新的抗癌药物筛选。近年来研究集中在蛋白质泛素化修饰与乳腺癌。在Cell Death Differ, Cancer Res, Oncogene, J Pathology, Nat Commun, Nat Genetics等国际重要学术刊物发表了近50篇SCI论文。申请人的H指数为22。在美国担任PI期间获得多项研究资助（总直接研究经费160万美元）。在蛋白质泛素化修饰研究领域有一定国际声誉。被国际会议和研究所邀请作报告100余次，同时被10多家机构邀请为基金评委（是自然科学基金委医学部肿瘤处二审专家），受邀为20多个SCI期刊审稿。

荣 获中国科学院地奥奖学金一等奖（1999）、美国癌症研究协会Scholar-in-Training奖（2002）、美国泌尿协会博士后奖学金 (2004)、佐治亚癌症联盟研究学者奖(2005)、美国癌症协会研究学者奖(2008)、Albany Medical College新教师奖(2009)、云南省高端科技人才(2010) 、中国科学院引进海外杰出人才（2011）以及自然科学基金委“杰出青年”基金(2013)等多项奖励。

8．王荣福，医学和药学博士，教授，主任医师，博士生导师，北京大学第一医院核医学科。教育部“核技术应用”重点学科学术带头人。现任北京大学医学部核医学系主任和北京大学第一医院核医学科主任，北京大学第一临床学院—美国霍普金斯大学医学院分子影像中心主任，第十届国家药典委员会委员，国家科学技术进步奖、中华医学科技奖和国家自然科学基金评审专家。全国高建委名医名院发展促进专业委员会核医学专业主任委员，中国医学装备协会核医学装备与技术专业委员会代理主任委员，中国核学会核医学分会副主任委员、中国抗癌协会肿瘤影像专业委员会副主任委员、中国医学装备协会核医学装备与技术专业委员会副主任委员、北京核学会副理事长，北京核学会核医学与分子影像专业委员会副主任委员及其他多个学术团体常委和国内外多种学术期刊编委和审稿专家。多次应邀参加国内外学术会议并大会报告和主持，承 担多项国家和部委级在研课题项目，主编教材和专著15部、参编40多部，发表400多篇论文（SCI收录40多篇），获3项中国发明专利、3项部委级科学 技术成果奖和1项教学成果奖。业务特长：主要从事分子与临床核医学，放射免疫显像与治疗，受体、反义与基因显像、肿瘤核素诊治、放射性药物研发及PET、 PET/CT和SPECT、SPECT/CT及动物PET、SPECT技术与临床应用研究等。

9．梁军，博士，教授，博士生导师。现北京大学国际医院肿瘤中心主任，原青岛大学医学院附属医院副院长、肿瘤中心主任。现任中国抗癌协会临床肿瘤学协作专业委员（CSCO） 副主任委员、中国抗癌协会临床肿瘤学协作专业委员会肝癌专家委员会副主任委员兼副组长，中国抗癌协会临床肿瘤学协作专业委员会恶性黑色素瘤专家委员会副主 任委员，中国抗癌协会临床肿瘤学协作专业委员会常委。《中国肿瘤临床》编委、《临床肿瘤学杂志》编委，《中华肿瘤防治杂志》编委，《齐鲁医学杂志》编委。 擅长胃癌、结直肠癌、胰腺癌、食管癌、胃肠道间质瘤、神经内分泌肿瘤的诊断及多学科综合治疗，在国内肿瘤领域享有盛名。

<